The emergence of hybridoma technology in 1975 has revolutionized the use of monoclonal antibodies (mAbs) as essential research tools, and more importantly, as highly successful molecules in clinical diagnosis and treatment. Considering relatively inefficient fusion, display technologies have been introduced ten years later for mAbs production, which is capable of displaying distinct antibodies 10⁷-10¹⁰. Limited by unnatural heavy and light chain pairing thorough random combination of VH and VL chain genes, a new method that directly samples single B cells from the host immune system for Native™ antibody discovery has been developed more recently.
Single B cell sorting, also known as B cell antibody technology, can high-throughput screen and generate fully human mAbs or natural antibody repertoire of different species in a short period, it is recognized as a powerful technique for therapeutic antibody development. Native™ antibody discovery by single B cell sorting technology generally is carried out in four steps:
Fig.1 Schematic of the single-B cell sorting for antibody discovery from immunized mice. (Starkie, et al., 2016)
Neurological disease is a class of disorders that affect the central or peripheral nervous system causing a range of mild or severe symptoms. Resulting from the tightly regulated blood-brain barrier in the central nervous system, therapy development for neurological disease is challenging and many preclinical studies are difficult to translate into clinical applications. Therapeutic mAbs are increasingly used in the treatment of various human diseases due to their remarkable targeting. By far, several mAbs have been approved for neurological disease treatment, mainly intending for multiple sclerosis, migraine headache, and glioblastoma. And many mAbs are being researched and assessed in preclinical and clinical trials for neuroimmunological and neurodegenerative conditions.
In 2020, a rabbit mAb against calcitonin gene-related peptides (CGRP) developed by single B cell sorting technology was approved for the remission and prevention of migraine, which was the beginning of therapeutic mAb development by single B cell sorting technology for neurological disease treatment. Native™ antibody discovery by single B cell sorting technology is a convenient and favorable method for the therapy development of neurological diseases, due to the advantages of shortening timeline and naturally paired antibody chains.
Creative Biolabs provides a series of products and a wide range of single B cell sorting-based technology Native™ antibody discovery services for neurological disease therapy development. If you are interested or have any questions, please feel free to contact us.
Reference
